Today: 19 May 2026
Browse Category

NYSE:RHHBY 17 July 2025 - 16 September 2025

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly will invest $5 billion to build a 200,000-square-foot drug manufacturing plant in Goochland County, Virginia, creating 650 permanent jobs and 1,800 construction jobs. The facility will produce active pharmaceutical ingredients for cancer and autoimmune treatments. The project is part of Lilly’s $27 billion U.S. expansion plan. Virginia approved over $10 million in incentives to secure the site.
16 September 2025
·······
Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Genentech is ending its $2 billion cell therapy partnership with Adaptive Biotechnologies, citing cost-cutting but no safety issues. Kriya Therapeutics raised $313 million in Series D funding, one of the year’s largest biotech rounds. The FDA delayed Neurizon’s ALS drug trial review until October due to staffing shortages. Stealth BioTherapeutics has resubmitted its elamipretide application for Barth syndrome after two FDA rejections.
19 August 2025
····
AI Pathology Breakthrough: Roche’s Lung Cancer Diagnostic Makes FDA History

AI Pathology Breakthrough: Roche’s Lung Cancer Diagnostic Makes FDA History

Roche’s Ventana TROP2 (EPR20043) RxDx test became the first AI-powered diagnostic to receive FDA Breakthrough Device Designation in April 2025. The system uses digital pathology and AI to classify NSCLC tumors as TROP2-positive or negative, guiding use of Datopotamab deruxtecan. In a retrospective analysis, TROP2-positive patients saw a 43% lower risk of progression or death with the drug versus chemotherapy.
17 July 2025
·

Stock Market Today

  • MoneyFlare Launches AI Trading Bot Amid Rising Institutional Interest in AI Infrastructure Stocks
    May 19, 2026, 2:23 PM EDT. MoneyFlare has introduced an AI Trading Bot designed to automate trading in crypto and stock markets. This launch coincides with growing institutional investor interest in AI infrastructure and semiconductor stocks, reflecting AI's increasing influence on market dynamics. The bot offers fully automated workflows, simplifying market monitoring, data analysis, and trade execution. It targets users seeking easier access to automated trading without complex setup or manual management. MoneyFlare aims to capitalize on volatility and sector rotation driven by AI trends, providing a user-friendly platform to engage with digital assets and equities through AI-powered strategies.

Latest articles

Astera Labs Moves Higher as Wall Street Eyes Next AI Bottleneck

Astera Labs Moves Higher as Wall Street Eyes Next AI Bottleneck

19 May 2026
Astera Labs shares surged 15.2% to $248.36 Tuesday after Evercore ISI raised its price target and management highlighted rising AI data-center demand. CEO Jitendra Mohan said revenue grew from $65 million at its 2024 IPO to $308 million last quarter. The company’s market value neared $45 billion, with shares trading at about 168 times earnings. One customer accounted for over 70% of projected 2025 revenue.
Recursion Stock Slumps to 52-Week Low as Traders Eye FDA News

Recursion Stock Slumps to 52-Week Low as Traders Eye FDA News

19 May 2026
Recursion Pharmaceuticals shares fell 2.2% to $2.825 Tuesday, hitting a 52-week low of $2.77, after reporting first-quarter revenue of $6.47 million, down from $14.75 million a year earlier. Net loss narrowed to $117.5 million. Early clinical data for REC-1245 showed no dose-limiting toxicities in 16 solid-tumor patients. The company ended March with $665.2 million in cash.
Wall Street’s Top Picks for U.S. Stocks as Yields Stay High

Wall Street’s Top Picks for U.S. Stocks as Yields Stay High

19 May 2026
U.S. stocks fell Tuesday as the 10-year Treasury yield reached its highest point since January 2025, pressuring growth shares. Nvidia drew the most attention ahead of its earnings, with options markets pricing in a possible $355 billion swing in value. Dell highlighted new AI infrastructure partnerships, while ServiceNow received a fresh Buy rating from Bank of America.
Go toTop